New test enables early diagnosis of liver cancer

September 19, 2013 by Toni Baker, Medical College of Georgia
Drs. Ravindra Kolhe, pathologist and Medical Director of the Georgia Esoteric, Molecular Labs, LLC, at the Medical College of Georgia at Georgia Regents University; Amyn Rojiani, Chairman of MCG's Department of Pathology; Andy Rahardja and Puneeta Vasa, pathology residents. Credit: Phil Jones

Researchers have found a way to make early liver cancer show its true colors. They have developed a test that will help pathologists clearly distinguish early liver cancer cells from nearly identical normal liver cells by giving them a distinctive red-brown hue.

The inability to definitively tell the difference often means the disease is detected late when treatment options are less effective, said Dr. Ravindra Kolhe, pathologist and Medical Director of the Georgia Esoteric, Molecular Labs, LLC, at the Medical College of Georgia at Georgia Regents University.

"There is no definitive test for early diagnosis of liver cancer," said Kolhe, lead author of the study being presented at the American Society of Clinical Pathology 2013 Annual Meeting in Chicago, Sept. 18-21. "Our test adds a level of comfort for making the diagnosis."

"The deadly liver seek to recapitulate the appearance of normal ," said Dr. Amyn M. Rojiani, Chairman of MCG's Department of Pathology. And they are very good at that, the pathologists agree, which is the frustration they have when trying to give patients definitive answers from looking at the tiny core biopsies of their liver under the microscope.

"As pathologists, we often find ourselves wanting to know more," said Dr. Andy Rahardja, a pathology resident who worked on the project. "Our test helps us differentiate between the two."

Unfortunately early liver cancer also is mostly silent. By the time it's large enough to cause classic symptoms such as abdominal pain and weight loss, the cancer cells look distinctive but the liver is failing. The myriad of treatment options - from removing the diseased portion of the liver to to freezing or heating cancer cells - have a high chance of failing as well, Kolhe said.

"You want to make the as early in the game as you can," Kolhe said. He began collaborating with BioGenex laboratories, a California company with expertise in cell and tissue testing, to develop a probe that gives cancer cells the distinctive red-brown hue. The probe detects and stains a microRNA called mir-21, which is found in liver cancer but not healthy liver cells, Kolhe said.

Unlike RNA, microRNA doesn't make proteins rather helps control proteins that are expressed by RNA. That means it's more stable and can survive harsh chemicals normally used to prepare the biopsy for microscopic evaluation. This includes using formaldehyde and replacing natural fluids with paraffin so the tissue can be easily cut and stained with different reagents to help pathologists try to pinpoint a patient's problem.

For the study, they used their probe on biopsies of 10 healthy livers and 10 livers with early cancers. In every case of liver cancer, the biopsy took on the red-brown hue. The probe was not detected in normal cells. The studies were done retrospectively, so they already knew which patients ultimately were diagnosed with cancer. They are now using the test on 200 similar cases of liver cancer.

The group also is exploring this approach in other hard-to-detect-early cancers. Kolhe worked with pathology resident Dr. Puneeta Vasa to identify microRNAs selectively expressed in melanoma. Under the microscope, the potentially deadly skin cancer cells look a lot like common mole cells. These findings also will be presented at the American Society of Clinical Pathology meeting and the researchers are working with BioGenex to develop probes to make melanoma-relevant microRNA stand out as well.

In the case of diagnosing early liver cancer, the physicians note that cirrhosis, a massive scarring of the liver resulting from chronic infection with hepatitis B and C viruses, further muddies the current diagnostic waters by essentially giving cancer cells cover. These common viruses are the most common cause of liver cancer worldwide, according to the American Cancer Society. Alcohol abuse, a leading cause of cirrhosis in the United States, also is a risk factor for . The new probe fortunately does not interact with cirrhosed cells, Kolhe said.

Explore further: Liver cancer due to chronic inflammation: Tumour growth follows programmed cell death (apoptosis)

Related Stories

Liver cancer due to chronic inflammation: Tumour growth follows programmed cell death (apoptosis)

August 30, 2013
The death of numerous liver cells in the context of chronic inflammation due to apoptosis, a form of programmed cell death, can promote the formation of tumour cells in the liver. This insight significantly contributes to ...

New study to combat the most common form of liver cancer

October 12, 2012
Scientists at the University of Southampton are to investigate the best way to use natural killer cells (NK) to target the most common form of liver cancer.

miR-122: Loss of tiny liver molecule might lead to liver cancer

July 23, 2012
A new study shows that loss of a small RNA molecule in liver cells might cause liver cancer and that restoring the molecule might slow tumor growth and offer a new way to treat the disease.

Study reveals much-needed strategy to protect against deadly liver fibrosis

August 15, 2013
Chronic liver disease is a leading cause of death in the United States, in part because it often causes the formation of harmful scar tissue—a process known as fibrosis. A study published by Cell Press August 15 in the ...

Hepatitis B virus promotes oncogenesis through microRNA modulation

January 16, 2013
Viruses prompt oncogenic transformation by genetically altering infected cells. Several recent studies have demonstrated that viruses alter the expression of microRNAs, non-coding RNA molecules that can block the expression ...

Recommended for you

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.